EA202091766A1 - Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике - Google Patents

Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике

Info

Publication number
EA202091766A1
EA202091766A1 EA202091766A EA202091766A EA202091766A1 EA 202091766 A1 EA202091766 A1 EA 202091766A1 EA 202091766 A EA202091766 A EA 202091766A EA 202091766 A EA202091766 A EA 202091766A EA 202091766 A1 EA202091766 A1 EA 202091766A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diagnostic
diagnostics
application
composition
diagnostic composition
Prior art date
Application number
EA202091766A
Other languages
English (en)
Inventor
Джонни Кастилло Мелеан
Томас Бетцель
Матиас Берндт
Ханно ШИФЕРШТАЙН
Хайко Крот
Жером МОЛЕТТ
Венсан ДАРМЕНСИ
Эмануэле Габелльери
Original Assignee
Ац Иммуне Са
Лайф Молекьюлар Имэджинг Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ац Иммуне Са, Лайф Молекьюлар Имэджинг Са filed Critical Ац Иммуне Са
Publication of EA202091766A1 publication Critical patent/EA202091766A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Polymerisation Methods In General (AREA)

Abstract

Настоящая заявка относится к композиции для диагностики, включающей a) соединение формулы Ib) этанол, c) воду и d) гидроксикарбоновую кислоту, соль гидроксикарбоновой кислоты или их смесь. Композиция для диагностики может быть использована для селективного выявления нарушений и аномалий, связанных с агрегатами Тау, таких как болезнь Альцгеймера (AD) и другие тауопатии, например, с помощью позитронно-эмиссионной томографии (ПЭТ). Настоящее изобретение также относится к способу получения заявленной композиции для диагностики.
EA202091766A 2018-01-24 2019-01-22 Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике EA202091766A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18153327 2018-01-24
PCT/EP2019/051497 WO2019145293A1 (en) 2018-01-24 2019-01-22 Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics

Publications (1)

Publication Number Publication Date
EA202091766A1 true EA202091766A1 (ru) 2021-02-18

Family

ID=61192647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091766A EA202091766A1 (ru) 2018-01-24 2019-01-22 Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике

Country Status (14)

Country Link
US (1) US20210047327A1 (ru)
EP (1) EP3743115A1 (ru)
JP (1) JP7260552B2 (ru)
KR (1) KR20200113241A (ru)
CN (1) CN111712265B (ru)
AU (1) AU2019210976B2 (ru)
BR (1) BR112020014594A8 (ru)
CA (1) CA3088232A1 (ru)
EA (1) EA202091766A1 (ru)
IL (1) IL275990B1 (ru)
MX (1) MX2020007487A (ru)
SG (1) SG11202006233XA (ru)
TW (1) TWI808119B (ru)
WO (1) WO2019145293A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019212170B2 (en) * 2018-01-24 2022-12-22 Ac Immune Sa Novel method of preparing an imaging compound
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
CN114832118B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 化合物i液体组合物、制备方法及其用途
CN114835690B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 含化合物i的液体组合物的制备方法、及在心肌灌注pet显像中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2421886T3 (es) * 2007-02-13 2013-09-06 Nihon Mediphysics Co Ltd Método para producción de un agente de representación de imágenes de diagnóstico por radiación
BRPI0820438A2 (pt) * 2007-11-07 2015-06-16 Ge Healthcare Bv Composição radiofarmacêutica estabilizada, método para a preparação da mesma, e, uso de ácido gentísico ou um sal do mesmo com um cátion biocompatível.
PL2381967T3 (pl) * 2008-12-31 2017-06-30 Avid Radiopharmaceuticals, Inc. Synteza styrylopirydyn radioznakowanych 18F z prekursorów tosylanowych i ich stabilne kompozycje farmaceutyczne
UY33152A (es) * 2009-12-23 2011-07-29 Bayer Schering Pharma Ag Formulaciones adecuadas para el diagnostico por imagenes con pet
CA2794808C (en) * 2010-04-16 2019-08-20 Ac Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
SG11201602786UA (en) * 2013-10-08 2016-05-30 Hoffmann La Roche Diazacarbazole derivatives as tau-pet-ligands
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
CN107198780A (zh) * 2016-03-18 2017-09-26 南京江原安迪科正电子研究发展有限公司 放射性药物组合物及其制备方法、应用
JP7059270B2 (ja) * 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
AU2017299219B2 (en) * 2016-07-22 2022-12-22 Ac Immune Sa Compounds for imaging Tau protein aggregates
WO2018024642A1 (en) * 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives

Also Published As

Publication number Publication date
CN111712265B (zh) 2024-02-09
WO2019145293A1 (en) 2019-08-01
SG11202006233XA (en) 2020-08-28
AU2019210976A1 (en) 2020-07-23
TW201932108A (zh) 2019-08-16
BR112020014594A8 (pt) 2022-12-13
JP7260552B2 (ja) 2023-04-18
IL275990A (en) 2020-08-31
BR112020014594A2 (pt) 2020-12-01
CA3088232A1 (en) 2019-08-01
IL275990B1 (en) 2024-04-01
TWI808119B (zh) 2023-07-11
MX2020007487A (es) 2020-09-14
CN111712265A (zh) 2020-09-25
AU2019210976B2 (en) 2024-04-18
KR20200113241A (ko) 2020-10-06
US20210047327A1 (en) 2021-02-18
EP3743115A1 (en) 2020-12-02
JP2021512070A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
EA202091766A1 (ru) Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике
TR201904041T4 (tr) Protein agregasyonu ile bağlantılı hastalıklarda ve/veya nörodejeneratif hastalıklarda rol oynayan proteinlerin agregasyonunu inhibe etmeye yönelik ilaçlar.
RU2505528C2 (ru) Соединения для применения в визуализации, диагностике и/или лечении заболеваний центральной нервной системы или опухолей
BR112016028345A2 (pt) composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto.
BR112015025140A2 (pt) 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem
WO2011097649A3 (en) Methods and apparatus for synthesizing imaging agents, and intermediates thereof
MX346101B (es) Sonda de formacion de imagen de tau.
WO2009155017A3 (en) Novel substituted azabenzoxazoles
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
BR112017015852A2 (pt) forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
TR201904514T4 (tr) Makrosiklik LRRK2 kinaz inhibitörleri.
MX2018016279A (es) Compuestos para formacion de imagenes de agregados de proteinas tau.
EP3834829A3 (de) Kompatibles solut oder solutgemisch (vorzugsweise ectoin bzw. ectoin-derivate) zur verwendung bei der prävention oder behandlung von krankheiten mit barrieredefekten in epithelgeweben
JP2018530608A5 (ru)
RU2016112547A (ru) Имидазо[1,2-а]пиридин-7-амины в качестве средств визуализации
BR112016027760A8 (pt) método de síntese de ph baixo de complexo de zinco-lisina
BRPI0917147B8 (pt) composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto
EA202091767A1 (ru) Новый способ получения визуализирующего соединения
WO2010051196A8 (en) Novel substituted azabenzoxazoles
WO2010096426A8 (en) Compounds, compositions, methods of synthesis, and methods of treatment
SG194759A1 (en) Novel precursors of glutamate derivatives
EA201300479A1 (ru) Соединения для применения в визуализации, диагностике и/или лечении заболеваний центральной нервной системы
Rossi et al. Anti-ganglioside specific auto-antibodies in ganglia of PDD-affected parrots
GB201115937D0 (en) 18F-labelled compounds for use as positron emission imaging agents